eoadjuvant DOS treatment for advanced esophageal cancer
Phase 2
Recruiting
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-jRCTs041210023
- Lead Sponsor
- Kodera Yasuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
1) Clinical stage II/III/IVa thoracic esophageal cancer
2) Histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma or basaloid-squamous cell carcinoma
3) Clinical T1-3
4) Ages between 20 years and 79 years
5) Performance status (PS) 0-1
6) Adequate function of vital organs, including bone marrow, liver, and kidney
7) Written informed consent
Exclusion Criteria
1) History (within 3 years) of malignancies
2) Active infectious disease
3) Psychiatric disease
4) Continuous systemic steroid therapy
5) Allergy of docetaxel, oxaliplatin or S-1
6) Persistent intestinal bleeding
7) Ineligible for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological response rate
- Secondary Outcome Measures
Name Time Method Overall survival time, disease-free survival time, R0 resection rate, response rate (RECIST v1.0), treatment completion rate, complication rate